Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Core Insights - Cytokinetics will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 2:15 PM Eastern Time [1] - The company is focused on developing a muscle biology franchise, particularly targeting cardiac and muscle dysfunction diseases [3] Company Overview - Cytokinetics is a specialty biopharmaceutical company with over 25 years of scientific innovation [3] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [3] - Aficamten is also being evaluated in additional trials for both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) [3] - Other products in development include omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies [3]